Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

If you wish to turn $10,000 into $50,000 by 2035, you’re looking at a 400% gain over a 10-year horizon. In the past decade, ...

Vanguard Primecap VPMCX continues to benefit from seasoned leadership, rock-bottom fees, and deep research. But even the best ...

If you sized SANA small after the May post, the thesis is tracking; consider letting winners run while watching for pullbacks ...

Merck MRK recently intensified its acquisition strategy, actively pursuing deals to enhance its development pipeline and ...

Leerink Partners trimmed its Q2 2025 earnings estimate for Eli Lilly to $5.40 per share, down from $5.54. Several firms ...

WW International relists on Nasdaq, pivoting to menopause care with GLP-1 drugs and coaching. Click here to read an analysis ...

Here's a breakdown of what you own when you put $10,000 into the S&P 500, including how many dollars are invested into the ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

The Cigna Group is set to report its Q2 2025 earnings on July 31, with analysts expecting a 6.3% profit jump year-over-year.